港股異動丨業績利好發酵 百勝中國-S(9987.HK)續升超5%創2個月新高
格隆匯2月11日丨百勝中國-S(9987.HK)續升超5%,績後2日漲幅達15%。盤中高見403.8港元創2個月新高價,暫成交2.43億港元,總市值1666億港元。公司2021年全年實現總收入98.5億美元,同比增加19%;淨利潤9.9億美元,同比增加26%。公司將於3月29日派發季度股息每股0.12美元。傑富瑞認為,百勝中國去年第四季度的淨利潤低於預期,但料隨着社交距離措施放鬆,市場於今年下半年有望復甦,維持對該股“買入”評級;瑞信指,百勝中國近期面臨壓力,但長期增長勢頭仍保持不變,予評級“跑贏大市”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.